Life sciences company Neogen (NASDAQ:NEOG) reported calendar Q3 2026 (fiscal Q1 2027) results beating Wall Street’s revenue expectations, with sales up 6.5% year on year to $222.8 million. The company expects the full year’s revenue to be around $887.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.08 per share was 50% above analysts’ consensus estimates.
Is now the time to buy NEOG? Find out in our full research report (it’s free for active Edge members).
Neogen (NEOG) Q3 CY2026 Highlights:
- Revenue: $222.8 million vs analyst estimates of $208.3 million (6.5% year-on-year growth, 7% beat)
- Adjusted EPS: $0.08 vs analyst estimates of $0.05 (50% beat)
- Adjusted EBITDA: $41.6 million vs analyst estimates of $36.67 million (18.7% margin, 13.5% beat)
- The company slightly lifted its revenue guidance for the full year to $887.5 million at the midpoint from $882.5 million
- EBITDA guidance for the full year is $182 million at the midpoint, above analyst estimates of $179.6 million
- Operating Margin: -0.8%, up from -7.7% in the same quarter last year
- Market Capitalization: $2.61 billion
StockStory’s Take
Neogen’s third quarter results showed progress in both its Food and Animal Safety segments, but the market reaction was negative. Management attributed the quarter’s performance to improved commercial execution, targeted customer engagement, and operational discipline. CEO Mikhael Nassif highlighted “tangible signs that the changes underway across Neogen are taking hold,” particularly with strengthened inventory planning and cross-functional collaboration. However, the company acknowledged that the timing of certain customer orders provided a temporary lift, suggesting the need for sustained improvement in core execution.
Looking ahead, Neogen’s guidance is shaped by ongoing investments in innovation, technology, and enterprise systems, with a focus on margin expansion and cash flow. Management expects accelerated investment in R&D and commercial capabilities to support long-term growth, while emphasizing continued transformation in operational efficiency. CFO Bryan Riggsbee noted that “investments in enterprise capabilities, technology solutions and automation” are expected to position the company for improved profitability. Management remains attentive to achieving a seamless transition in Petrifilm production while maintaining customer continuity and cost discipline.
Key Insights from Management’s Remarks
Neogen’s management highlighted three priorities shaping recent results and future strategy: commercial execution, innovation, and operational efficiency, with notable updates in each area during the quarter.
- Commercial execution gains: Management reported early evidence of success from segment-focused initiatives and strategic account targeting, with improved sales KPI reviews enabling faster adjustments and stronger pipeline management, especially in global strategic accounts.
- Innovation pipeline investment: The company accelerated R&D spending and announced a new partnership with Hinalea for hyperspectral imaging. CEO Nassif explained how this technology could simplify food safety workflows, detecting issues earlier and supporting automation.
- Operational efficiency focus: Teams have adopted more disciplined planning and supply chain management, leading to better inventory positioning, cost control, and visibility across global operations. Initiatives like black belt-led projects and enhanced operating reviews were cited as drivers for margin expansion.
- Petrifilm manufacturing transition: The multi-quarter transfer of this critical product line remains on track, with full validation of the first SKU completed. Management emphasized the importance of customer continuity, safety stock, and disciplined sequencing to minimize risk and financial impact.
- Divestiture and capital structure moves: Progress continues on the planned sale of the genomics business, with expected proceeds earmarked for debt reduction. Management also used existing cash balances to pay down term loan obligations, aiming to bring net leverage below 3x post-closing.
Drivers of Future Performance
Neogen’s outlook is driven by continued investment in innovation and operational improvements, balanced against cost headwinds and a focus on long-term margin expansion.
- R&D and commercial investment: Management is prioritizing higher spending in research, product development, and commercial infrastructure to strengthen Neogen’s leadership in food safety and animal health. These investments are expected to support future revenue growth but may pressure near-term margins.
- Operational transformation and cost control: Initiatives in supply chain, inventory optimization, and automation are aimed at driving efficiency and expanding adjusted EBITDA margins over time. The Petrifilm manufacturing transition is a key milestone, with anticipated cost savings and improved scalability after full transfer.
- Market and regulatory dynamics: Management remains watchful for macroeconomic pressures on food producers and evolving regulatory requirements that could affect demand for safety testing. Risks include elevated input costs for farmers and the need for disciplined execution during ongoing business transformation.
Catalysts in Upcoming Quarters
Going forward, the StockStory team will monitor (1) the successful execution of the Petrifilm manufacturing transition and associated cost reduction, (2) the pace and impact of new product innovation and partnerships, and (3) progress on operational efficiency initiatives that support margin expansion. The upcoming closure of the genomics divestiture and its effect on the balance sheet will also be key metrics for assessing Neogen’s execution against its strategy.
Neogen currently trades at $11.76, down from $11.99 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
High Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.